• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Datatrak Q3 Sales Drop by a Third, Loss Narrows

Datatrak Q3 Sales Drop by a Third, Loss Narrows

November 17, 2009
CenterWatch Staff

Datatrak International, a technology and services company focused on eClinical solutions, reported third quarter revenues fell 34% to $1.55 million compared with the prior year quarter but its net loss narrowed.

Compared to the prior year third quarter, combined direct cost and selling, general and administrative expenses decreased approximately $1.8 million, or nearly in half.

Datatrak reported a net loss of $(424,000), or $(0.03) per share on a basic and diluted basis, compared with a net loss of $(1.6 million), or $(0.12) per share on a basic and diluted basis, for the same time period of 2008.  Last year's third quarter net loss included a charge of $835,000 related to its German subsidiary office closing. In addition, the company's financial results for the prior year third quarter were negatively impacted by legal costs of $234,000 associated with litigation, which was favorably concluded in December 2008 resulting in the forgiveness of $3 million previously owed by Datatrak.

At Sept. 30, backlog was $8.89 million compared with $8.55 million at June 30. The Sept. 30 backlog amount represents the first quarter-over-quarter increase in backlog since the first quarter of 2008.

During the third quarter, the company’s cash balance declined $303,000 to $1.33 million at Sept. 30., compared with $1.63 million as of June 30.

"We believe the increase in backlog is a very good indicator that clinical trial sponsors are ready to move forward with projects which were on hold earlier this year,” said Laurence Birch, chairman of the board of Datatrak.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing